TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7640054
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of ifosfamide (3 g/m2 every 24 h for 3 days)
Study: 1904568
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg transdermal E2 patches for 2 weeks, followed by 0.1 mg patches for 4 weeks (immediate ERT)
Study: 1904568
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg transdermal E2 patches for 2 weeks, followed by 0.1 mg patches for 4 weeks (delayed ERT)
Study: 1904568
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg transdermal E2 patches
Study: 26695758
Drug: Natesto™ Testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natesto™ Testosterone Nasal Gel (11 mg b.i.d. or 11 mg t.i.d.)
Study: 26695758
Drug: Natesto™ Testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natesto™ Testosterone Nasal Gel (titration arm)
Study: 26695758
Drug: Natesto™ Testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natesto™ Testosterone Nasal Gel (fixed-dose arm)
Study: 26695758
Drug: Natesto™ Testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natesto™ Testosterone Nasal Gel
Study: 23474648
Drug: High-protein/calorie parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein/calorie parenteral nutrition (HPC-PN)
Study: 23474648
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard parenteral nutrition)
Study: 23168752
Drug: Long-acting reversible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting reversible contraceptive (LARC) methods (IUDs and implants) provided at no cost
Study: 28805670
Drug: Salacia Chinensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salacia Chinensis (300 mg)
Study: 28805670
Drug: Salacia Chinensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salacia Chinensis (500 mg)
Study: 28805670
Drug: Salacia Chinensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salacia Chinensis (300 mg) or (500 mg)
Study: 25623753
Drug: Subcutaneous delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous delivery of trastuzumab via Single Injectable Device (SID)
Study: 25623753
Drug: Subcutaneous delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous delivery of trastuzumab via hand-held syringe (HHS)
Study: 25623753
Drug: Intravenous delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous delivery of trastuzumab
Study: 21406054
Drug: Various antiretroviral
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various antiretroviral drugs
Study: 21406054
Drug: Older and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older and lesser used drugs
Study: 21406054
Drug: Recently approved
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recently approved drugs
Study: 21406054
Drug: Compounds under
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounds under investigation
Study: 25891543
Drug: Caffeine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (150 mg daily at 10 a.m.)
Study: 25891543
Drug: Placebo (n=2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (n=2) or no treatment (n=1)
Study: 15868252
Drug: Topical GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical GTN (5 ml, 1 mg/ml)
Study: 7726425
Drug: Lidocaine 45
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 45 mg and epinephrine 15 micrograms (Group 5)
Study: 7726425
Drug: Lidocaine 45
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 45 mg (Group 2)
Study: 7726425
Drug: Lidocaine 45
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 45 mg and epinephrine 5 micrograms (Group 3)
Study: 7726425
Drug: Lidocaine 45
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 45 mg and epinephrine 10 micrograms (Group 4)
Study: 2029201
Drug: Long-term administration
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term administration group (L) receiving Cyclophosphamide (CPA) at a total dose of 25 g/m2 over 18 months
Study: 2029201
Drug: Short-term administration
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term administration group (S) receiving Cyclophosphamide (CPA) at a total dose of 6 g/m2 over 6 months
Study: 2029201
Drug: Long-term administration
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term administration group (L)
Study: 117442
Drug: Pre-operative parenteral
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative parenteral nutrition over a 7-10 day period
Study: 29420227
Drug: Azithromycin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 7.5 mg/kg, 5 days/week for 4 weeks and 3 days/week for another 4 weeks with metronidazole 20 mg/kg/day for 8 weeks (group 1)
Study: 28194668
Drug: Raw rhubarb
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw rhubarb solution (250 cases drank a raw rhubarb soak solution per 3 hours until defecation after ERCP)
Study: 28194668
Drug: Raw rhubarb
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw rhubarb solution
Study: 14764781
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone application (Virormone, 5 mg) for 8 or 12 hours
Study: 10833890
Drug: Moxonidine 40
Normalized name: moxonidine 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 40 mg alone in the morning
Study: 10833890
Drug: Moxonidine 40
Normalized name: moxonidine 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 40 mg in combination with melatonin 3 mg overnight
Study: 9752921
Drug: Aspiration and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration and injection of steroid
Study: 8411611
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg in the morning
Study: 3085212
Drug: Phenoxymethylpenicillin, 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin, 12.5 mg/kg body weight, administered orally 30-240 min before surgery
Study: 28651550
Drug: C3 (2
Normalized name: Codeine.
Approvals — FDA: no, EMA: no, PMDA: no
Description: C3 (2 mg/mL) applied four times daily for 2 weeks
Study: 17259696
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 600 mg/day for 12 weeks
Study: 11756055
Drug: Low-fat, complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, complex carbohydrate diet (LF-CC)
Study: 9803986
Drug: Methotrexate (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (oral or intramuscular doses weekly)
Study: 7659386
Drug: Jet nebulizer
Normalized name: Pari LC Jet Nebulizer Plus RE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet nebulizer (Respirgard II) with 2 ml volume fill (R2)
Study: 7659386
Drug: Ultrasonic nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic nebulizer (Ultraneb 99) with 4 ml volume fill (U4)
Study: 26037798
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and gemcitabine (CisGem) chemotherapy
Study: 23569146
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) for 12 weeks
Study: 23569146
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy alone (non‐CRT group)
Study: 17093157
Drug: Two tests
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tests of glucose solution as the reference
Study: 15286687
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) and Cyclosporin A (CsA) combination
Study: 9394582
Drug: Aspirin discontinued
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin discontinued two days before operation (Group I)
Study: 9394582
Drug: Aspirin continued
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin continued up to operation (Group II)
Study: 9394582
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aspirin for at least seven days before operation)
Study: 3678266
Drug: Propafenone (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (450 mg to 900 mg per day)
Study: 29082595
Drug: Nitrate supplementation
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplementation (25 ml beetroot juice, one shot per day for 3 days)
Study: 19947907
Drug: SC ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC ceftriaxone with rHuPH20 (350 mg/mL)
Study: 15655130
Drug: Lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoic acid 300 mg/d
Study: 15655130
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/d and Lipoic acid 300 mg/d
Study: 12805489
Drug: UK‐279,276 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK‐279,276 (1.0 mg/kg)
Study: 12805489
Drug: UK‐279,276 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK‐279,276 (1.5 mg/kg)
Study: 12805489
Drug: UK‐279,276 (0.06,
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK‐279,276 (0.06, 0.1, 0.2, 0.5, 1.0, 1.5 mg/kg)
Study: 12805489
Drug: UK‐279,276 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK‐279,276 (1.0 and 1.5 mg/kg)
Study: 6208468
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with cyclophosphamide combined with Ara‐C
Study: 6208468
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with Cyclo‐C
Study: 6208468
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of VP‐16 and CCNU to maintenance therapy
Study: 28145073
Drug: Dermalax implant
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermalax implant plus™
Study: 19705681
Drug: Integrated ICPS
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated ICPS drug and employment counseling (n = 12)
Study: 19705681
Drug: ICPS drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICPS drug counseling control condition (n = 11)
Study: 17012300
Drug: Tigecycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (100 mg intravenous infusion over 30 min)
Study: 12431972
Drug: Study agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study agent (cytostatic agent)
Study: 9927265
Drug: Low-dose vancomycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vancomycin (500 mg/d)
Study: 9927265
Drug: High-dose vancomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vancomycin (2 g/d)
Study: 9927265
Drug: Metronidazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1 g/d)
Study: 8745203
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and sulfonylurea
Study: 7004720
Drug: Bendrofluazide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (10 mg daily) for 3 days
Study: 7004720
Drug: Bendrofluazide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (10 mg daily) for 10 weeks
Study: 6882732
Drug: Malted cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malted cocoa drink fortified with FePO4 and ascorbic acid (1 mg/g powder)
Study: 26758281
Drug: Ebselen (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebselen (3600 mg over 24 h)
Study: 22009510
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg oral naproxen sodium plus active TENS
Study: 22009510
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg oral naproxen sodium plus placebo TENS
Study: 18581586
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of parecoxib
Study: 18581586
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of proparacetamol
Study: 20179234
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant endocrine treatment
Study: 12172717
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tenoxicam in 25 ml normal saline
Study: 12172717
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine in 25 ml normal saline
Study: 12172717
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml normal saline (control)
Study: 10199760
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion (10% at 150 mL/h)
Study: 7493372
Drug: IFN-alpha (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha (3 million units daily for 14 days)
Study: 7493372
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IFN-alpha treatment)
Study: 2097909
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 5%
Study: 2097909
Drug: Topical benzocaine
Normalized name: benzocaine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzocaine 20% vs Topical lidocaine 5%
Study: 2097909
Drug: Topical anesthetics
Normalized name: topical anesthetics (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthetics (benzocaine 20% and lidocaine 5%)
Study: 18799080
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) treatment
Study: 30807516
Drug: Intravitreal 0.5‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal 0.5‐mg ranibizumab
Study: 28800951
Drug: High-concentration contrast
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration contrast media (HCCM) injection protocol with low tube current (effective mAs reduced by a factor of 0.6, HCCM 400 mgI/mL)
Study: 28800951
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration contrast medium (300 mgI/mL) with automatic mAs
Study: 23787155
Drug: High Hb
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Hb group (target Hb 11.0 ≤ target Hb ≤ 13.0 g/dL with darbepoetin alfa)
Study: 23787155
Drug: Low Hb
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Hb group (target Hb 9.0 ≤ target Hb ≤ 11.0 g/dL with recombinant human erythropoietin)
Study: 21636031
Drug: UFH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH plus glycoprotein IIb/IIIa inhibitor (control group)
Study: 1544739
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg caffeine with exercise (running for 30 min at 75% of maximum heart rate)
Study: 1544739
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg caffeine without exercise
Study: 3916264
Drug: Self-initiated treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-initiated treatment
Study: 27312538
Drug: Menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal hormone therapy (MHT) cream containing oestradiol 50mcg and norethisterone acetate 140mcg
Study: 19170463
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg, fixed‐flexible dose)
Study: 16791541
Drug: Once-daily modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily modified-release MPH (EqXL) at doses of 20, 40, or 60 mg
Study: 16791541
Drug: Twice-daily immediate-release
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily immediate-release methylphenidate (MPH-IR) at doses of 10, 20, or 30 mg
Study: 15531675
Drug: Beta-carotene (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (15 mg/d)
Study: 9314869
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen (doxorubicin 25 mg/m2 on days 1-3 and cisplatin 100 mg/m2 on day 1 for six cycles over 18 weeks)
Study: 9314869
Drug: Multi-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug regimen (preoperatively vincristine, high-dose methotrexate, and doxorubicin; postoperatively bleomycin, cyclophosphamide, dactinomycin, vincristine, methotrexate, doxorubicin, and cisplatin over 44 weeks)
Study: 1824
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg d-amphetamine with lithium carbonate
Study: 1824
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg l-amphetamine with lithium carbonate
Study: 28482692
Drug: Baseline heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline heart rate (per 5 bpm increase) without β-blockers
Study: 25845224
Drug: Acupoint-injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint-injection of BCG polysaccharide nucleic acid
Study: 25845224
Drug: Intramuscular-injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular-injection of BCG polysaccharide nucleic acid
Study: 22459649
Drug: Volumetric Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volumetric Modulated Arc Therapy (RapidArc)
Study: 15526012
Drug: rHuEpo (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo (300 units per kg per dose, subcutaneous, for 10 days) plus oral iron
Study: 10563709
Drug: Lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 150 mg twice a day
Study: 10563709
Drug: Lamivudine 300
Normalized name: lamivudine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 300 mg twice a day
Study: 10563709
Drug: Lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 150 mg and 300 mg regimens
Study: 9494257
Drug: Amtolmetin guacyl
Normalized name: Amtolmetin guacil
DrugBank: Amtolmetin guacil (DB16088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetin guacyl (1200 mg/day for first 3 days, then 600 mg/day for remaining 27 days)
Study: 9494257
Drug: Diclofenac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (150 mg/day in three daily administrations on a full stomach)
Study: 18713921
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (5 mg)
Study: 18713921
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (5-15 mg)
Study: 10472510
Drug: High-dose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (25 mg) nicotine patch therapy
Study: 10472510
Drug: Standard-dose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (15 mg) nicotine patch therapy
Study: 8117635
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% bupivacaine with epinephrine
Study: 3767037
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 mg X kg‐1)
Study: 3767037
Drug: Droperidol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (0.1 mg X kg‐1)
Study: 26472043
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) with loading dose (400 mg Weeks 0/2/4)
Study: 26472043
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) without loading dose
Study: 26472043
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) with loading dose
Study: 24798614
Drug: First-line antiretroviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line antiretroviral therapy (efavirenz or nevirapine with zidovudine/lamivudine or tenofovir/lamivudine)
Study: 24798614
Drug: First-line antiretroviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line antiretroviral therapy (in Nigeria)
Study: 23169985
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading followed by 90 mg bid
Study: 23169985
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading followed by 10 mg od
Study: 10226872
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (4 x 200 mg/day, p.o.)
Study: 8709351
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen withdrawal with 300 mg cyproterone acetate daily for 12 weeks
Study: 26001387
Drug: Citalopram (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (30 mg single dose)